Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.43 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | AHCY | P23526 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29770525 | 1.00 | PRMT6 (0.47) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL5557366 | 0.93 | PRMT6 (0.48) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL5557369 | 0.93 | PRMT6 (0.48) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL16648583 | 0.92 | PRMT6 (0.47) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23989259 | 0.92 | PRMT6 (0.45) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL21333923 | 0.92 | PRMT6 (0.46) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL3219117 | 0.89 | PRMT6 (0.47) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL28602758 | 0.89 | PRMT6 (0.47) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL28602756 | 0.89 | PRMT6 (0.47) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23243930 | 0.87 | ACHE (0.42) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2026-04-16 | — | — | US | disclosed |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2024-11-14 | — | — | US | disclosed |
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | SANOFI (FR) | 2024-02-13 | — | — | US | disclosed |
| US-20220372063-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2022-11-24 | — | — | US | disclosed |
| EP-4025582-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2022-07-13 | — | — | EP | disclosed |
| US-20210115075-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI (FR) | 2021-04-22 | — | — | US | disclosed |
| WO-2021044004-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2021-03-11 | — | — | WO | disclosed |
| CN-112105625-A | Nucleotide precursors, nucleotide analogs, and oligomeric compounds containing the same | 赛诺菲 | 2020-12-18 | — | — | CN | disclosed |
| EP-1015469-B2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2015-11-18 | — | — | EP | disclosed |
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-20100279895-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2010-11-04 | — | — | US | disclosed |
| US-20100267018-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2010-10-21 | — | — | US | disclosed |
| US-7572582-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2009-08-11 | — | — | US | disclosed |
| US-7034133-B2 | Locked Nucleoside Analogues is a biochemical conjugate of nucleotides; as an aptamer in specific binding of antibiotics, drugs, amino acids, peptides, enzymes, saccharides, polysaccharides; heat resistance | EXIQON A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | QIAGEN GMBH (DE) | 2005-12-29 | — | — | US | disclosed |
| EP-1557424-A1 | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues | Exiqon A/S (DK) | 2005-07-27 | — | — | EP | disclosed |
| EP-1015469-B1 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2005-04-13 | — | — | EP | disclosed |
| US-6794499-B2 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES | EXIQON A/S (DK) | 2004-09-21 | — | — | US | disclosed |
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | disclosed |
| US-20030134808-A1 | Oligonucleotide analogues | WENGEL JESPER (DK) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | RNMT, RRM2B, RRM2 | PRMT6 2309/4885PRKAB2 1615/4885PRKAG1 1366/4885 |
| US-20210115075-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | RNMT, RRM2B, RRM2 | PRMT6 2309/4885PRKAB2 1615/4885PRKAG1 1366/4885 |
| US-20030134808-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | PRMT6 4729/4885PRKAB2 4103/4885PRKAG1 3408/4885 |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | NSUN2, NSUN3, SNRPA | PRMT6 3122/4885PRKAB2 1358/4885PRKAG1 1147/4885 |
| US-20100267018-A1 | OLIGONUCLEOTIDE ANALOGUES | POLRMT, POLM, POLN | PRMT6 4771/4885PRKAB2 3638/4885PRKAG1 3277/4885 |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | POLRMT, POLM, POLN | PRMT6 4752/4885PRKAB2 3198/4885PRKAG1 2689/4885 |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | RNMT, NSUN2, ADAR | PRMT6 3618/4885PRKAB2 953/4885PRKAG1 736/4885 |
| US-20220372063-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | DCLRE1B, UPF1, IGF2BP1 | PRMT6 3356/4885PRKAB2 910/4885PRKAG1 914/4885 |
| US-20100279895-A1 | OLIGONUCLEOTIDE ANALOGUES | POLRMT, POLM, POLN | PRMT6 4771/4885PRKAB2 3638/4885PRKAG1 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.